prophylact
effect
human
interferon
huifn
test
natur
acquir
rhinoviru
infect
largescal
field
trial
desir
show
selfadministr
drug
practic
determin
smallest
welltoler
dose
like
produc
worthwhil
effect
report
selfadminist
intranas
interferon
effect
show
prophylaxi
rhinoviru
infect
affect
quantiti
interferon
interv
dose
viru
challeng
final
medic
regimen
suggest
use
field
trial
mu
timesday
test
doubleblind
placebocontrol
trial
volunt
although
viru
challeng
time
treat
interferon
would
suscept
substanti
protect
effect
still
demonstr
peopl
experi
cold
year
patient
may
develop
sever
lower
respiratori
tract
diseas
cold
exampl
children
wheezi
bronchiti
suffer
chronic
bronchiti
cold
caus
rhinovirus
mean
prevent
rhinoviru
cold
would
consider
valu
clinic
practic
volunt
trial
common
cold
unit
shown
human
interferon
produc
recombin
dna
techniqu
escherichia
coli
administ
physician
highli
effect
protect
rhinoviru
infect
largescal
field
trial
prophylaxi
natur
acquir
rhinoviru
infect
administr
physician
would
practic
trial
undertaken
interferon
must
shown
effect
selfadministr
intranas
spray
addit
minim
dose
like
produc
worthwhil
prophylact
effect
must
determin
interest
economi
minimis
likelihood
side
effect
report
seri
experi
protect
effect
variou
dose
regimen
huifnct
experiment
rhinoviru
infect
examin
studi
approv
ethic
committe
northwick
park
hospit
harrow
result
accumul
seri
day
trail
involv
volunt
healthi
volunt
sex
age
yr
recruit
screen
suitabl
hous
isol
group
common
cold
unit
accord
usual
procedur
initi
blood
sampl
taken
haematolog
biochem
test
includ
estim
electrolyt
provid
serum
determin
neutralis
antibodi
human
rhinoviru
type
volunt
accomod
unit
flat
divid
group
occup
match
age
sex
one
group
alloc
interferon
treatment
placebo
administr
procedur
reduc
risk
treatment
error
ensur
one
treatment
schedul
repres
flat
everi
trial
occup
flat
group
challeng
salin
remain
volunt
given
nasal
drop
contain
follow
h
later
geometr
mean
dose
calcul
back
titrat
respect
interferon
placebo
treatment
start
day
viru
salin
challeng
continu
day
blood
sampl
obtain
haematolog
biochemistri
end
period
look
chang
could
attribut
medic
clinic
effect
monitor
observ
unawar
alloc
volunt
volunt
assess
daili
given
daili
score
basi
sign
symptom
clinic
respons
grade
nil
doubt
mild
mild
moder
sever
cold
paper
handkerchief
use
volunt
weigh
order
estim
daili
nasal
secret
nasal
wash
viru
isol
collect
day
prior
day
viru
challeng
serum
sampl
request
volunt
wk
leav
unit
titrat
parallel
initi
sampl
estim
neutralis
antibodi
hrv
volunt
exclud
trial
develop
sign
cold
viru
challeng
extern
rhinoviru
recov
prechalleng
nasal
wash
sampl
scheringplough
purifi
mega
unit
mu
mg
protein
dissolv
phosphat
buffer
salin
pb
stabilis
mgml
human
serum
albumin
lyophilis
placebo
lyophilis
human
serum
albumin
pb
reconstitut
distil
water
scheringplough
intranas
spray
use
deliv
ilactiv
interferon
placebo
kept
maximum
h
except
final
trial
interferon
given
timesday
occas
merthiol
mgml
ad
preserv
interferon
placebo
prepar
kept
whole
period
medic
dark
room
temperatur
volunt
familiaris
spray
contain
pb
day
medic
began
volum
solut
deliv
medic
determin
weigh
spray
use
inform
use
calcul
mean
quantiti
interferon
dose
one
dose
alway
consist
activ
spraynostril
frequenc
medic
timesday
dose
supervis
physician
nasal
wash
sampl
collect
test
presenc
rhinovirus
hela
cell
strain
virusneg
wash
retest
addit
equal
volum
antihuman
leucocyt
interferon
antibodi
dilut
contain
neutralis
uml
kindli
suppli
dr
k
fant
wellcom
research
laboratori
beckenham
kent
least
one
isol
infect
volunt
test
use
mixtur
antisera
neutralis
demonstr
extern
rhinovirus
recognis
characterist
cytopath
effect
acid
labil
serum
neutralis
antibodi
estim
use
micromethod
previous
describ
differ
frequenc
cold
viru
isol
antibodi
rise
test
signific
use
test
yate
correct
clinic
score
nasal
secret
viru
excret
data
evalu
use
mannwhitney
u
test
pharmacokinet
studi
scheringplough
spray
produc
intranas
level
neutralis
antibodi
titr
whichev
lower
b
plevel
statist
signific
interferon
placebotr
group
interferon
similar
achiev
risdon
gun
davi
et
al
press
therefor
chose
spray
examin
protect
effect
interferon
selfadminist
volunt
placebocontrol
trial
medic
given
timesday
pm
day
viru
challeng
given
h
dose
mean
quantiti
dose
mu
result
viru
challeng
summaris
tabl
mild
moder
sever
cold
amongst
interferon
recipi
compar
mild
wors
cold
placebo
recipi
p
number
volunt
produc
one
virusposit
nasal
wash
sampl
viru
shedder
reduc
interferon
compar
placebo
group
significantli
howev
incid
antibodi
rise
reduc
significantli
p
also
larg
signific
reduct
clinic
score
nasal
secret
proport
volunt
excret
viru
reduc
significantli
day
challeng
fig
placebocontrol
trial
investig
protect
effect
lower
daili
dose
calcul
dose
mu
placebo
given
day
start
day
viru
challeng
continu
day
volunt
challeng
viru
h
second
dose
mild
wors
cold
amongst
interferon
recipi
compar
neutralis
antibodi
titr
whichev
lower
b
plevel
statist
signific
interferon
placebotr
group
placebo
recipi
p
tabl
although
fewer
volunt
antibodi
rise
viru
shedder
interferon
placebotr
group
reduct
reach
statist
signific
howev
larg
signific
reduct
clinic
score
nasal
secret
accompani
signific
reduct
proport
volunt
excret
viru
day
challeng
fig
prophylaxi
success
trial
spite
reduc
dose
interferon
may
viru
challeng
close
follow
second
dose
investig
possibl
repeat
studi
interv
h
second
interferon
dose
viru
challeng
similar
respons
challeng
interferon
placebotr
group
tabl
although
fewer
cold
antibodi
rise
interferontr
group
reduct
signific
signific
differ
two
group
either
clinic
score
nasal
secret
viru
excret
consist
trend
variabl
suggest
prophylact
effect
interferon
fig
therefor
conclud
treatment
detect
protect
effect
trial
next
examin
well
volunt
protect
rhinoviru
challeng
variou
dose
hulfn
experi
volunt
given
interferon
mean
quantiti
dose
mu
twice
daili
pm
interferon
given
either
viru
challeng
might
expect
protect
neutralis
antibodi
titr
whichev
lower
b
plevel
statist
signific
interferon
placebotr
group
fig
clinic
score
nasal
secret
viru
excret
volunt
treat
intranas
interferon
challeng
mu
selfadminist
day
day
viru
challeng
given
h
second
dose
none
observ
differ
statist
signific
dose
equal
effect
time
greatest
suscept
viru
infect
would
half
way
howev
interferon
given
viru
challeng
produc
greater
protect
effect
given
afterward
suscept
would
increas
interv
interferon
dose
exposur
viru
identifi
time
greatest
suscept
viru
infect
volunt
experi
challeng
viru
h
h
third
dose
interferon
result
viru
challeng
summaris
tabl
clinic
laboratori
paramet
infect
similar
mu
mu
treatment
group
consist
reduc
mu
h
viru
challeng
group
time
viru
challeng
consist
effect
clinic
laboratori
evid
infect
lower
dose
treatment
group
consist
reduct
variabl
h
compar
h
challeng
group
mudos
given
signific
trend
determin
analysi
varianc
categor
variabl
frequenc
cold
viru
isol
day
frequenc
viru
isol
antibodi
rise
significantli
reduc
mu
treatment
group
p
scheff
test
reduct
incid
cold
reach
signific
viru
challeng
h
h
signific
effect
clinic
laboratori
paramet
infect
continu
variabl
transform
log
e
x
overcom
skew
distribut
signific
effect
interferon
concentr
total
clinic
score
p
effect
reach
signific
nasal
secret
weight
differ
clinic
score
larg
result
low
score
mu
treatment
group
time
viru
challeng
signific
effect
variabl
result
experi
led
us
conclud
intranas
dose
least
mu
given
timesday
might
necessari
produc
substanti
protect
effect
natur
acquir
rhinoviru
infect
therefor
final
placebocontrol
trial
given
suitabl
formul
present
see
materi
method
prophylact
efficaci
rhinoviru
challeng
medic
given
timesday
pm
day
volunt
challeng
viru
receiv
interferon
might
expect
suscept
infect
h
fourth
dose
mean
quantiti
hulfnct
dose
mu
one
volunt
exclud
analysi
extern
rhinoviru
recov
prechalleng
nasal
wash
two
volunt
one
interferon
placebotr
prechalleng
neutralis
antibodi
titr
virus
exclud
resist
infect
result
viru
challeng
remain
volunt
summaris
tabl
mild
wors
cold
amongst
volunt
receiv
interferon
compar
amongst
placebo
recipi
statist
signific
number
viru
shedder
antibodi
rise
also
slightli
reduc
interferontr
group
statist
signific
howev
proport
volunt
excret
viru
day
viru
challeng
nasal
secret
clinic
score
day
viru
challeng
variabl
significantli
reduc
fig
twentyfour
volunt
challeng
salin
given
placebo
haematolog
biochem
abnorm
blood
sampl
volunt
given
interferon
reaction
medic
summaris
tabl
proport
volunt
increas
nasal
secret
similar
interferon
placebotr
group
obviou
relationship
quantiti
nasal
secret
produc
dose
interferon
clinic
symptom
mainli
mild
nasal
symptom
report
frequent
interferon
placebo
recipi
mean
total
clinic
score
interferontr
group
higher
placebotr
group
obviou
relationship
dose
one
volunt
receiv
lowest
dose
interferon
mu
mild
cold
accumul
total
clinic
score
doubl
daili
quantiti
produc
day
preced
start
medic
experi
variou
dosag
schedul
evalu
protect
effect
challeng
virul
rhinovirus
two
strain
type
type
use
order
increas
frequenc
infect
clinic
symptom
object
experi
arriv
regimen
suitabl
test
largescal
prophylact
trial
huifna
appar
well
toler
day
dosag
level
given
howev
evid
mild
local
inflamm
volunt
mild
nasal
symptom
produc
obvious
doserel
suffici
magnitud
obscur
benefici
effect
interferon
treatment
feasibl
selfadministr
prove
conclus
doubleblind
placebocontrol
trial
given
timesday
experi
mild
moder
sever
cold
consid
signific
invari
accompani
laboratori
evid
infect
either
viru
isol
antibodi
rise
demonstr
also
occur
salinechalleng
volunt
signific
cold
produc
viru
challeng
interferontr
volunt
interferon
protect
challeng
hrv
data
shown
howev
experi
surpris
degre
protect
produc
singl
daili
dose
decay
undetect
level
within
h
experi
dose
interferon
vari
mu
twice
day
significantli
greater
protect
effect
mu
mu
howev
volunt
treat
mu
challeng
viru
h
third
dose
develop
cold
consist
statist
signific
trend
toward
protect
mu
treatment
group
interv
third
dose
interferon
viru
challeng
rather
h
suggest
given
h
viru
challeng
greater
protect
effect
given
h
afterward
interv
fourth
dose
interferon
follow
viru
challeng
h
challeng
group
harmon
et
al
shown
antivir
state
induc
interferon
may
persist
nasal
epitheli
cell
obtain
biopsi
least
h
interferon
treatment
experi
conduct
vitro
use
sensit
techniqu
reduct
yield
vsv
experi
measur
clinic
respons
rhinoviru
challeng
may
insuffici
sensit
detect
larg
effect
viru
replic
found
protect
clinic
symptom
decay
rapidli
rel
larg
amount
intranas
administ
necessari
order
prevent
cold
protein
solut
rapidli
clear
nose
halflifetim
approxim
rain
high
concentr
interferon
may
maintain
smaller
daili
dose
frequenc
dose
rather
quantiti
dose
increas
increas
dose
frequenc
might
also
lessen
interv
medic
interferon
follow
natur
exposur
viru
howev
frequenc
dose
increas
detriment
complianc
base
practic
consider
result
volunt
experi
conclud
regimen
selfadminist
interferon
approxim
mudos
timesday
would
appropri
evalu
largescal
field
trial
prophylaxi
natur
acquir
rhinoviru
infect
suitabl
formul
present
test
placebocontrol
trial
volunt
sought
demonstr
minimum
protect
effect
regimen
although
volunt
challeng
rhinoviru
time
receiv
interferon
might
expect
suscept
infect
h
fourth
dose
substanti
protect
effect
still
demonstr
interferon
treatment
produc
signific
reduct
clinic
laboratori
evid
infect
although
protect
complet
signific
cold
amongst
treat
volunt
natur
exposur
rhinovirus
might
expect
occur
frequent
dose
interferon
also
dose
viru
use
challeng
volunt
experi
may
larger
normal
encount
natur
therefor
recognis
less
intens
medic
regimen
could
prove
effect
prophylact
natur
acquir
rhinoviru
cold
howev
benefici
effect
drug
may
less
easili
detect
field
trial
care
control
volunt
studi
reproduc
condit
experi
unfavour
prophylaxi
might
expect
occur
natur
tri
ensur
dosag
regimen
chosen
would
substanti
protect
effect
natur
acquir
rhinoviru
infect
studi
progress
determin
whether
mild
nasal
symptom
experienc
volunt
take
intranas
reach
unaccept
level
longterm
administr
